These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26464271)

  • 21. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
    Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
    Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets.
    Goudemand J; Mazurier C; Samor B; Bouquelet S; Montreuil J; Goudemand M
    Thromb Haemost; 1985 Jun; 53(3):390-5. PubMed ID: 2864750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
    Aly AM; Hoyer LW
    J Clin Invest; 1992 May; 89(5):1382-7. PubMed ID: 1569181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease.
    Schwarz HP; Schlokat U; Mitterer A; Váradi K; Gritsch H; Muchitsch EM; Auer W; Pichler L; Dorner F; Turecek PL
    Semin Thromb Hemost; 2002 Apr; 28(2):215-26. PubMed ID: 11992244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles.
    Furlan M; Perret BA; Beck EA
    Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
    Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic.
    Kawasaki T; Kaida T; Arnout J; Vermylen J; Hoylaerts MF
    Thromb Haemost; 1999 Feb; 81(2):306-11. PubMed ID: 10064011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virus harvesting in perfusion culture: Choosing the right type of hollow fiber membrane.
    Nikolay A; de Grooth J; Genzel Y; Wood JA; Reichl U
    Biotechnol Bioeng; 2020 Oct; 117(10):3040-3052. PubMed ID: 32568408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation, activity and inactivation of factor VIII in factor VIII products.
    Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
    Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
    Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
    Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
    Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.